Health Care & Life Sciences


Eli Lilly making renewed push in biotech field, where it once pioneered

August 16, 2014
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.More.

After strong trials, Lilly to seek approvals for psoriasis drug

August 21, 2014
The drug company said Thursday its drug ixekizumab cleared away skin inflammation in six times as many patients as the blockbuster drug Enbrel. Lilly is in a race to bring the first in a new-class of psoriasis treatments to market.More.

Lilly wins tentative approval for diabetes drug

August 20, 2014
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.More.

Cardinal Health unit seeks tax breaks for local drug facility

August 18, 2014
A subsidiary of Dublin, Ohio-based Cardinal Health Inc. is seeking tax breaks from the city of Indianapolis to help it open a $14.4 million local drug-production facility that would employ 85 workers by 2017.More.



In Depth Report

BioCrossroads has stoked state's life sciences industry, but challenges remainRestricted Content

In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.More.

SPECIAL REPORT: Indiana companies charge into China

With economic growth in the United States sluggish, Indiana companies are joining the race to capitalize on the fast-growing Chinese economy—even as hundreds of millions of Chinese move into the middle class and adopt a Western-style thirst for goods and services.More.

Hospitals suffer from spiking bond interest rates, investment lossesRestricted Content

Indianapolis-area hospitals have suffered a double whammy of spiking interest rates on their bonds and heavy losses in their investment portfolios and are trying to save cash any way they can.More.

In Depth Reports

Sponsored by
Subscribe to IBJ
  1. I always appreciate your thoughtful comments, so let me try to understand this one better. Can you tell me what you mean by illogical in regards to the Mathematica and Ball State research? Do you mean that the results just don't ring true? Or did you have something else in mind? As for the Mathematica report being old, it's a fair point. However, there has been nothing like it done for Indiana since then. And much of the social science research cited in policymaking and debates is far older. For example, the key research folks use to advocate for publicly funded preschool is 40-50 years old. So I don't think 10 makes something irrelevant, unless more recent research has shown it to be.

  2. JK - You raise some good points but your references to all these so-called studies confuse the issue. On the surface, some of the studies seem to be illogical. For example, the Mathematica report is over 10 years old and seems illogical to me; is it still relevant? The "recent" research by Ball State regarding the results of 6 vs 8 jobs also seems illogical. Moreover, you have given us a data dump without really taking us through a good analysis. I have come to expect that from you. Nevertheless, I will probably look through the methodologies of some of the studies you cite to see if they appear to have credibility; I am always skeptical that they have political agendas that are not apparent. Anyway, thanks for continuing to raise issues regarding the stat of health care in Indiana.

  3. Medicaid is not health insurance, it is a price fixing scheme run by the government.